
SCYNEXIS SCYX
$ 0.64
-0.03%
Quarterly report 2025-Q3
added 11-05-2025
SCYNEXIS Total Shareholders Equity 2011-2026 | SCYX
Annual Total Shareholders Equity SCYNEXIS
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 73 M | 3.23 M | 41.3 M | 22.8 M | 12.9 M | 31.2 M | 21.4 M | 34.8 M | 41.9 M | 33.4 M | -108 M | -65.4 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 73 M | -108 M | 11.9 M |
Quarterly Total Shareholders Equity SCYNEXIS
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 36.4 M | 44.5 M | 50.5 M | 55.1 M | 58.5 M | 60.4 M | 74.1 M | 73 M | 92 M | 93.1 M | -29.9 M | 3.23 M | 17.2 M | 45.5 M | 38.9 M | 41.3 M | 37.6 M | 32.3 M | 25.9 M | 22.8 M | 22.8 M | 22.8 M | 22.8 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 31.2 M | 31.2 M | 31.2 M | 31.2 M | 21.4 M | 21.4 M | 21.4 M | 21.4 M | 34.8 M | 34.8 M | 34.8 M | 34.8 M | 41.9 M | 41.9 M | 41.9 M | 41.9 M | 33.4 M | 33.4 M | 33.4 M | 33.4 M | -108 M | -108 M | -108 M | -108 M | -65.4 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 93.1 M | -108 M | 22 M |
Total Shareholders Equity of other stocks in the Drug manufacturers industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M | ||
|
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-808 K | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
487 M | $ 1.2 | 0.42 % | $ 129 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
8 M | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | ||
|
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
14.8 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
-6.6 B | - | - | $ 28.9 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
1.01 B | - | -0.1 % | $ 2.03 B | ||
|
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | ||
|
HEXO Corp.
HEXO
|
557 M | - | 2.45 % | $ 38.1 M | ||
|
Emergent BioSolutions
EBS
|
649 M | $ 12.84 | 2.8 % | $ 657 M | ||
|
Athenex
ATNX
|
-6.51 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | $ 21.5 | -0.12 % | $ 2.05 B | ||
|
Evolus
EOLS
|
5.52 M | $ 6.03 | -10.27 % | $ 374 M | ||
|
Harrow Health
HROW
|
70.8 M | $ 54.06 | 8.3 % | $ 1.76 B | ||
|
Jupiter Wellness
JUPW
|
-2.17 M | - | - | $ 33.6 M | ||
|
China Pharma Holdings
CPHI
|
7.75 M | $ 1.23 | 1.65 % | $ 21.5 M | ||
|
OrganiGram Holdings
OGI
|
300 M | $ 1.7 | -1.74 % | $ 402 M | ||
|
Bausch Health Companies
BHC
|
-1.02 B | $ 7.51 | 4.16 % | $ 2.74 B | ||
|
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | ||
|
Neoleukin Therapeutics
NLTX
|
186 M | - | - | $ 193 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
22.9 M | $ 3.95 | -0.77 % | $ 55.5 M | ||
|
Organogenesis Holdings
ORGO
|
263 M | $ 4.36 | -5.93 % | $ 574 M | ||
|
Sundial Growers
SNDL
|
270 M | $ 1.72 | -1.41 % | $ 3.37 M | ||
|
Pacira BioSciences
PCRX
|
778 M | $ 25.21 | 3.07 % | $ 1.17 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 3.73 | 2.46 % | $ 4.63 M | ||
|
Aurora Cannabis
ACB
|
2.13 B | $ 4.28 | -1.41 % | $ 86.3 M | ||
|
Rockwell Medical
RMTI
|
21.3 M | $ 0.98 | 13.92 % | $ 22.9 M | ||
|
PetIQ
PETQ
|
223 M | - | 1.64 % | $ 400 M | ||
|
Perrigo Company plc
PRGO
|
4.32 B | $ 14.36 | 3.42 % | $ 1.97 B | ||
|
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | ||
|
Veru
VERU
|
32.3 M | $ 2.28 | 0.58 % | $ 308 M | ||
|
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | ||
|
cbdMD
YCBD
|
1.96 M | $ 1.11 | -4.31 % | $ 4.79 M | ||
|
Relmada Therapeutics
RLMD
|
85.4 M | $ 4.11 | -6.06 % | $ 124 M | ||
|
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
138 M | $ 9.62 | 5.25 % | $ 683 M | ||
|
PLx Pharma
PLXP
|
35.7 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
137 M | $ 5.33 | -2.14 % | $ 218 M | ||
|
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
3.32 B | $ 9.43 | -3.03 % | $ 5.83 B | ||
|
TherapeuticsMD
TXMD
|
29.3 M | $ 1.79 | 8.78 % | $ 18.7 M | ||
|
Zomedica Corp.
ZOM
|
240 M | - | -0.21 % | $ 98 M |